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Spectrum of gluten-related disorders: consensus
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Katri Kaukinen8, Kamran Rostami9, David S Sanders10, Michael Schumann11, Reiner Ullrich11, Danilo Villalta12,
Umberto Volta13, Carlo Catassi1,14 and Alessio Fasano1*
Abstract
A decade ago celiac disease was considered extremely rare outside Europe and, therefore, was almost completely
ignored by health care professionals. In only 10 years, key milestones have moved celiac disease from obscurity
into the popular spotlight worldwide. Now we are observing another interesting phenomenon that is generating
great confusion among health care professionals. The number of individuals embracing a gluten-free diet (GFD)
appears much higher than the projected number of celiac disease patients, fueling a global market of gluten-free
products approaching $2.5 billion (US) in global sales in 2010. This trend is supported by the notion that, along
with celiac disease, other conditions related to the ingestion of gluten have emerged as health care concerns. This
review will summarize our current knowledge about the three main forms of gluten reactions: allergic (wheat
allergy), autoimmune (celiac disease, dermatitis herpetiformis and gluten ataxia) and possibly immune-mediated
(gluten sensitivity), and also outline pathogenic, clinical and epidemiological differences and propose new
nomenclature and classifications.
Introduction
Wheat, rice and maize are the most widely consumed
food grains in the world. Wheat, the most widely grown
crop, is immensely diverse, with more than 25,000 dif-
ferent cultivars having been produced by plant breeders
worldwide. Much of the world’s production of wheat is
consumed after it has been processed into bread, other
baked goods, pasta and noodles, and, in the Middle East
and North Africa, bulgur and couscous. In addition, the
wide availability of wheat flour and the functional prop-
erties of gluten proteins provide the rationale for their
wide use as an ingredient in food processing.
Gluten is the main structural protein complex of
wheat with equivalent toxic proteins found in other cer-
eals, including rye and barley. The toxic protein frac-
tions of gluten include gliadins and glutenins, with
gliadins containing monomeric proteins and glutenins
containing aggregated proteins. Possibly the introduction
of gluten-containing grains, which occurred about
10,000 years ago with the advent of agriculture, repre-
sented an evolutionary challenge that created the condi-
tions for human diseases related to gluten exposure, the
best known of which are mediated by the adaptive
immune system: wheat allergy (WA) and celiac disease
(CD). In both conditions the reaction to gluten is
mediated by T-cell activation in the gastrointestinal
mucosa. However, in WA it is the cross-linking of
immunoglobulin (Ig)E by repeat sequences in gluten
peptides (for example, serine-glutamine-glutamine -glu-
tamine-(glutamine-)proline-proline-phenylalanine) that
triggers the release of chemical mediators, such as hista-
mine, from basophils and mast cells [1]. In contrast, CD
is an autoimmune disorder, as demonstrated by specific
serologic autoantibodies, most notably serum anti-tissue
transglutaminase (tTG) and anti-endomysial antibodies
(EMA).
Besides CD and WA, there are cases of gluten reac-
tions in which neither allergic nor autoimmune mechan-
isms are involved. These are generally defined as gluten
sensitivity (GS) [2-5]. Some individuals who experience
distress when eating gluten-containing products and
show improvement when following a GFD may have GS
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instead of CD. GS patients are unable to tolerate gluten
and develop an adverse reaction when eating gluten that
usually, and differently from CD, does not lead to
damage in the small intestine. While the gastrointestinal
symptoms in GS may resemble those associated with
CD, the overall clinical picture is not accompanied by
the concurrence of tTG autoantibodies or other specific
celiac-related antibodies. Currently the diagnosis is
made by exclusion, and an elimination diet and ‘open
challenge’ (that is, the monitored reintroduction of glu-
ten-containing foods) are most often used to evaluate
whether health improves with the elimination of or
reduction in gluten from the diet. However, this
approach lacks specificity and is subject to the risk of a
placebo effect of the elimination diet in improving
symptoms.
The diversity of gluten-induced conditions is in line
with the notion that the immune system reacts to and
deals with the triggering environmental factor, gliadin,
in distinct ways. Here we systematically review the spec-
trum of gluten-related disorders and propose new
nomenclatures to fill the gaps of current classifications
(Figure 1).
Methods
In order to develop a consensus on new nomenclature and
classification of gluten-related disorders, a panel of 15
experts was convened in London in February 2011. Each
expert was assigned a specific topic that was then collec-
tively discussed and consensus was achieved when each
panelist agreed on specific definitions and nomenclature.
Based on the discussion and the current evidence in litera-
ture, the panel generated a series of definitions and created
the classifications and algorithms summarized below.
Allergic reactions (onset: minutes to hours after gluten
exposure)
Wheat allergy
WA is defined as an adverse immunologic reaction to
wheat proteins. Depending on the route of allergen
exposure and the underlying immunologic mechanisms,
WA is classified into classic food allergy affecting the
skin, gastrointestinal tract or respiratory tract; wheat-
dependent, exercise-induced anaphylaxis (WDEIA);
occupational asthma (baker’s asthma) and rhinitis; and
contact urticaria. IgE antibodies play a central role in
the pathogenesis of these diseases.
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Figure 1 Proposed new nomenclature and classification of gluten-related disorders.
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Epidemiology In a population-based birth cohort in
Stockholm, the prevalence of sensitization to wheat in
2,336 four-year-old children was reported to be 4%
[6,7], decreasing over time [8]. Another, longitudinal,
study of 273 children from ages two to ten years
reached contrary conclusions, showing that the preva-
lence of IgE to wheat progressively increased with age,
from 2% to 9% [9]. In adults in the United States, a list-
assisted random-digit-dial survey by the US Food and
Drug Administration found a 0.4% prevalence of initially
self-reported and later on doctor-diagnosed wheat and/
or gluten allergy [10]. In a systematic review by Zuidm-
eer et al. [11], two population-based studies from the
UK and one from Germany reported positive wheat
challenge tests in children, with a prevalence as high as
0.5%. In adults, the prevalence of sensitization to wheat
(assessed by IgE) was higher (> 3% in several studies)
than perceived (< 1%). With respect to heritability, an
ongoing family-based food allergy cohort study in the
USA revealed that the estimated heritability of food-spe-
cific IgE was statistically significant for all nine tested
food allergens, including wheat [12].
Clinical presentations Much of the research on adverse
allergic reactions to wheat has focused on respiratory
allergy (baker’s asthma), which is one of the most preva-
lent occupational allergies in many countries. Dietary
allergy to wheat, which in its extreme form may lead to
anaphylaxis and death, is probably less widespread in
the general population. The proteins that are responsible
for a dietary allergy in wheat are also less clearly defined
than those contributing to baker’s asthma, but recent
studies indicate that there are intriguing similarities and
differences between the two conditions.
Baker’s asthma
Recognized since the time of the Roman Empire,
baker ’s asthma and rhinitis are well-characterized
allergic responses to the inhalation of wheat and cer-
eal flours and dusts [13]. A Polish study discovered
that chest respiratory symptoms ascribed to baker’s
asthma were observed in 4.2% of bakery apprentices
after only one year and in 8.6% after two years [14].
The corresponding values for allergic rhinitis were
8.4% and 12.5%, respectively. Diagnosis is usually
based on skin prick tests and the demonstration of
specific IgE antibodies (for example, anti-wheat, -bar-
ley and -rye ﬂour IgE as well as anti-a-amylase IgE in
serum). Little was known about the proteins responsi-
ble for baker’s asthma until the application of electro-
phoresis combined with immunochemistry in the
1970s. Such early studies showed that multiple aller-
gens were present, with the water-soluble albumins
being particularly reactive with the IgE fractions from
patients’ sera [13]. More recent studies have identified
individual proteins, which are recognized by IgE from
patients’ sera. It is clear that one group of wheat pro-
teins contains the most important allergens, the a-
amylase inhibitors. However, a number of other pro-
teins present in wheat, including germ agglutinin, per-
oxidase and non-speciﬁc lipid transfer proteins
(LTPs), have been reported to bind to IgE from
patients with baker’s asthma [13]. It is of interest that
both peroxidase and LTP have also been reported to
be active in food allergy to wheat [13].
Food allergy
Allergic responses to the ingestion of wheat can be
divided into two types. WDEIA is a well-defined syn-
drome that is caused by a specific type of grain protein,
ω5-gliadins. Other allergic responses include atopic der-
matitis, urticaria and anaphylaxis and appear to be
related to a range of wheat proteins. These may vary
between populations and be related to age and symp-
toms. Studies with purified proteins using IgE specific
assays with patients’ sera showed that 60% had IgE to
a-gliadins, b-gliadins and low molecular weight subu-
nits, 55% to g-gliadins, 48% to ω-gliadins, and 26% to
high molecular weight subunits [13]. All patients with
anaphylaxis or WDEIA and 55% of those with urticaria
had IgE to ω5-gliadins [13].
Wheat-dependent exercise-induced anaphylaxis
Patients with WDEIA display a range of clinical symp-
toms, from generalized urticaria to severe allergic reac-
tions including anaphylaxis. Using synthetic peptides,
scientists have identified seven epitopes (QQIPQQQ,
QQLPQQQ, QQFPQQQ, QQSPEQQ, QQSPQQQ,
QQYPQQQ and PYPP) within the primary sequence of
ω5-gliadins as the major allergens. Four of these epi-
topes were found to be dominant: QQIPQQQ,
QQFPQQQ, QQSPEQQ and QQSPQQQ. Mutational
analysis of the QQIPQQQ and QQFPQQQ peptides
indicated that the amino acids at positions glutamine-1,
proline-4, glutamine-5, glutamine-6 and glutamine-7
were critical for IgE binding [13].
Diagnosis Skin prick tests and in vitro IgE assays are
first-level diagnostics for WA. However, the positive
predictive value of these tests is less than 75%, particu-
larly in adults due to the cross-reactivity with grass pol-
lens. In addition, many commercial reagents for skin
prick tests have a low sensitivity since they are mixtures
of water- and salt-soluble wheat proteins that lack aller-
gens from the insoluble gliadin fraction. Testing prick
by prick using only raw material partially overcomes
this problem, and in many cases an oral food challenge
is necessary for the final diagnosis of food allergy. In
recent years a large variety of wheat grain proteins have
been identified and characterized as allergens. Some of
them are now available for component resolved diagno-
sis in WA with an increase of diagnostic accuracy of the
in vitro IgE assays. There is no evidence that identifying
Sapone et al. BMC Medicine 2012, 10:13
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serum-IgG antibodies to wheat or gliadin indicates the
presence of disease.
Autoimmune reactions (onset: weeks to years after gluten
exposure)
Celiac disease
CD is an immune-mediated enteropathy triggered by the
ingestion of gluten in susceptible individuals. The onset
of symptoms is usually gradual and characterized by a
time lag of months or years after gluten introduction.
Nevertheless, in patients on long-term treatment with a
GFD, the ingestion of gluten may occasionally cause
immediate symptoms, such as vomiting and abdominal
pain.
Epidemiology CD is one of the most common disorders
in countries predominantly populated by people of Eur-
opean origin (for example, Europe, North and South
America and Australia) affecting approximately 1% of
the general population. Interestingly, recent studies indi-
cate a trend toward a rising prevalence of CD during
the last several decades for reasons that are currently
unclear [15,16]. Epidemiological studies have provided
evidence that this disorder is also common in other
parts of the world, including North Africa, the Middle
East and part of the Asian continent. CD frequency is
likely to increase in many developing countries, due to
the progressing ‘Westernization’ of the diet. For
instance, in many Asian countries, a sharp decrease of
consumption of rice per capita and a parallel increased
consumption of wheat-based products is taking place.
Rising income and urbanization are driving forces in the
increase in wheat consumption. Whereas wheat is con-
sidered an ordinary food in Western societies, in tradi-
tional rice-eating Asian countries, wheat is becoming a
preferred staple [15]. Because of these alimentary trends,
an increasing incidence of CD in Asian countries can be
anticipated in the near future.
Pathogenesis Genetic predisposition plays a key role in
CD, and considerable progress has been made recently
in identifying genes that are involved [17-19]. It is well
known that CD is strongly associated with specific
human leukocyte antigen (HLA) class II genes, known
as HLA-DQ2 and HLA-DQ8, located on chromosome
6p21. Most CD patients (approximately 95%) express
genes encoding the major histocompatibility complex
(MHC) class II protein HLA-DQ2. The remaining
patients are usually HLA-DQ8-positive. The HLA-DQ2
haplotype is common and is carried by approximately
30% of Caucasian individuals, implying that the presence
of HLA-DQ2 and/or HLA-DQ8 is necessary for disease
development but not sufficient on its own as its esti-
mated risk effect is only 36% to 53%. On the other
hand, non-HLA genes collectively contribute more than
HLA to the CD genetic background. However, this
predisposition depends on a multitude of genes, each of
them adding only a modest contribution to disease
development [20].
Gliadin-specific T-cell responses have been found to
be enhanced by the action of intestinal tTG. Although
there are at least 50 T-cell-stimulatory epitopes in
gluten proteins, a unique 33-mer gliadin fragment
(Figure 2, yellow motif) is the most immunogenic pep-
tide [21]. Moreover, it is resistant to enzymatic degrada-
tion by gastric, pancreatic and brush border peptidases.
Altered processing by intraluminal enzymes, changes in
intestinal permeability and activation of innate immunity
seem to precede the activation of the adaptive immune
response.
Clinical presentations and diagnosis The clinical spec-
trum of CD is wide (Figure 1) and includes symptomatic
cases with either classical intestinal (for example,
chronic diarrhea, weight loss) or non-classical extrain-
testinal (for example, anemia, osteoporosis, neurological
disturbances) features and silent forms that are occa-
sionally discovered because of serological screening.
Additionally, potential forms of the disease, in which the
auto-antibodies are detected while the autoimmune
insult of the intestinal mucosa is not present, have been
described (Figure 1). CD prevalence is increased in at-
risk conditions, such as a family history of CD, autoim-
mune diseases, IgA deficiency, some genetic syndromes
(Down, Turner and William syndromes) and especially
type 1 diabetes and thyroiditis. Due to atypical features,
many CD cases currently escape diagnosis and are
exposed to the risk of long-term complications, for
example, infertility and lymphoma, even if it is now
appreciated that the prevalence of these complications is
lower than previously reported.
Specific and sensitive serological tests are available as
an initial test for CD. Measurement of IgA antibodies to
tTG (anti-tTG) is recommended for initial testing for
CD, while IgA anti-EMA is considered as a confirmatory
test. More recently, deamidated gliadin peptides (DGP)
antibodies (especially of the IgG class) have been intro-
duced with sensitivity and specificity comparable to
anti-tTG and anti-EMA, but with possibly a better per-
formance in IgA-deficient subjects and in children
younger than three years [22,23]. A high level of anti-
tTG (and possibly anti-DGP) and anti-EMA antibodies
(10 × or higher) is almost invariably associated with a
typical celiac enteropathy found through biopsy of the
small intestine [24]. Individuals with CD who are IgA
deficient will not have abnormally elevated levels of IgA
anti-tTG or IgA anti-EMA and need to be screened
with IgG-based tests. A small intestinal biopsy is an
important diagnostic investigation that should be under-
taken in many patients with suspected CD. The charac-
teristic histological changes include an increased
Sapone et al. BMC Medicine 2012, 10:13
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number of intraepithelial lymphocytes (IELs) (> 25 lym-
phocytes per 100 enterocytes), elongation of the crypts,
partial to total villous atrophy and a decreased villous:
crypt ratio [25]. Polymerase chain reaction sequence-
specific oligonucleotide typing methods are now avail-
able for the determination of alleles encoding HLA-DQ2
and HLA-DQ8. Since the HLA predisposing genotype is
a necessary factor for disease development, the negative
predictive value of HLA typing is very high, that is, the
vast majority of subjects who are HLA-DQ2- and HLA-
DQ8-negative will never develop CD.
The wide variability of CD-related findings suggests
that it is difficult to conceptualize the diagnostic process
into rigid algorithms that can cover the clinical com-
plexity of this disease. For this reason, a quantitative
approach that can be defined as the ‘four out of five
rule’ was proposed recently[26]. Using this method, the
diagnosis of CD is confirmed if at least four of the fol-
lowing five criteria are fulfilled:
1. Typical symptoms of CD
2. Positivity of serum CD IgA class autoantibodies at
high titer
3. HLA-DQ2 and/or HLA-DQ8 genotypes
4. Celiac enteropathy found on small bowel biopsy
5. Response to a GFD
Dermatitis herpetiformis
Dermatitis herpetiformis (DH) is a skin manifestation of
CD presenting with blistering rash and pathognomonic
cutaneous IgA deposits [27]. DH was named by Duhring
in 1884, though his original description covered several
disorders including pemphigus and erythema
multiforme.
Epidemiology DH occurs most commonly in individuals
of European origin. The prevalence is approximately one
in 10,000 in the UK and is the same in the USA among
the white population of European descent, although
higher rates of four and six per 10,000 have been
reported from Sweden and Finland, respectively [27].
DH seldom occurs in Asians or Africans. DH can pre-
sent at any age, but is rare at the extremes of life; the
mean age at presentation is about 40 years. In contrast
with CD, DH is more common in men than in women
(1.5 to 1.9:1). Family studies indicate that 5% of first-
degree relatives also will have DH and an additional 5%
will have CD. Both DH and CD show the same high
prevalence of HLA-DQ2 (90%) and HLA-DQ8 (5%) hap-
lotypes [28].
Pathogenesis It is not known why only some patients
with CD develop DH and what factors link the bowel
and skin lesions. In DH, IgA is present in the skin, and
Figure 2 Mapping of a-gliadin motifs. Those exerting cytotoxic activity are shown in red, immunomodulatory activity in yellow, zonulin release
and gut permeating activity in blue, and CXCR3-dependent IL-8 release in celiac disease patients in dark green. Partially modified from [60].
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inflammatory cells and cytokines are found in the
lesions. Furthermore, anti-EMA and anti-tTG antibodies
occur in the serum, and the rash is gluten-sensitive. The
importance of these factors and how they interact to
produce skin lesions remains unknown, though recently
antibodies directed at epidermal transglutaminase (TG3)
have been identified in patients with DH and this may
be the dominant autoantigen in the disorder [29].
Clinical features and diagnosis The earliest skin
abnormalities consist of a small erythematous macule,
which rapidly develops into an urticarial papule. Small
vesicles appear that may rupture, dry and form scabs.
The predominant symptoms are intense itching and
burning. The rash has a characteristic symmetrical dis-
tribution. The elbows and upper forearms are affected
in more than 90% of patients. Other sites commonly
involved are the buttocks, knees, shoulders, sacrum,
face, scalp, neck and trunk. The rash may be wide-
spread, but can be limited to one or two sites. Once
the rash appears, it is an ongoing problem in most
patients, but it can run an intermittent course in 10%
of cases. Only a minority of patients, about 10%, have
gastrointestinal symptoms and these are usually mild.
However, celiac-type villous atrophy in the upper small
intestinal mucosa is found in 65% to 75% of patients
with DH. Even in patients with apparently normal
biopsies, subtle changes in the mucosa, such as an
increased number of IELs, indicate gluten sensitization.
A celiac-type pattern of autoantibodies (anti-tTG, anti-
EMA and anti-DGP antibodies) is usually found in the
serum of patients with DH. Likewise, DH patients may
show the same array of manifestations, associated dis-
orders and complications as in patients with CD (auto-
immune diseases, iron-deficient anemia, osteoporosis
and malignancy).
The diagnosis of DH rests on the demonstration of
IgA in uninvolved skin on biopsies analyzed by immu-
nofluorescence staining. The most common site is in
the dermal papillae, where IgA is detected as granular
or fibrillar deposits. IgA may also be laid down in a lin-
ear granular fashion along the line of the basement
membrane. It is important that this pattern is differen-
tiated from homogeneous linear IgA deposition found in
linear IgA disease, which is not gluten dependent. Diag-
nosis of DH is based on skin biopsy and serological evi-
dence of celiac-type autoimmunity. Since DH is the
cutaneous counterpart of CD (’skin CD’), a proven diag-
nosis of DH in a patient should be taken as indirect evi-
dence for the presence of small bowel damage.
Accordingly, a duodenal biopsy is unnecessary in DH
patients [30].
After establishing a diagnosis of DH, GFD implemen-
tation should be recommended, even when the small
intestinal mucosa appears normal (as is the case in
potential CD), because the rash of DH is gluten
sensitive.
Gluten ataxia
Gluten ataxia (GA) was originally defined as otherwise
idiopathic sporadic ataxia with positive serological mar-
kers for gluten sensitization [31]. Like CD, it is an auto-
immune disease characterized by damage to the
cerebellum resulting in ataxia.
Epidemiology A series of 800 patients with progressive
ataxia evaluated over a period of 15 years in Sheffield,
UK, found that 148 out of 635 patients (23%) with
sporadic ataxia had serological evidence of gluten sensi-
tization (M. Hadjivassiliou, personal communication). A
number of studies looking at the prevalence of anti-glia-
din antibodies (AGA) in ataxias have been published
[32-35]. The common theme in most of these studies is
the consistently high prevalence of AGA in sporadic
ataxias when compared to healthy controls.
Pathogenesis There is evidence to suggest that there is
antibody cross-reactivity between antigenic epitopes on
Purkinje cells and gluten proteins [36-38]. Widespread
deposition of transglutaminase antibodies has been
found around brain vessels in patients with GA. The
deposition is most pronounced in the cerebellum, pons
and medulla. Antibodies against tTG6, a primarily
brain-expressed transglutaminase, have been found in
patients with GA [39-41]. In GA and DH, IgA deposits
seem to accumulate in the periphery of vessels where in
healthy TG6 or TG3, respectively, these are not usually
found [42].
Using a mouse model, it has recently been shown that
serum from GA patients, as well as clonal monovalent
anti-tTG Igs derived using phage display, causes ataxia
when injected intraventricularly in mice [43]. These data
therefore provide evidence that anti-tTG Igs (derived
from patients) compromise neuronal function in
selected areas of the brain, suggesting that this involves
an immune-system independent mode of action.
Clinical presentation and diagnosis GA usually pre-
sents with pure cerebellar ataxia or, rarely, ataxia in
combination with myoclonus, palatal tremor or opsoclo-
nus myoclonus. GA is usually of insidious onset with a
mean age at onset of 53 years. Rarely, the ataxia can be
rapidly progressive. Gaze-evoked nystagmus and other
ocular signs of cerebellar dysfunction are seen in up to
80% of cases. All patients have gait ataxia, and the
majority have limb ataxia. Less than 10% of patients
with GA will have any gastrointestinal symptoms, but a
third will have evidence of enteropathy on biopsy.
Nevertheless, an intestinal biopsy is indicated when
serum tTG2 antibodies are elevated. Up to 60% of
patients have neurophysiological evidence of sensorimo-
tor, length-dependent axonal neuropathy. This is usually
mild and does not contribute to the ataxia. Up to 60%
Sapone et al. BMC Medicine 2012, 10:13
http://www.biomedcentral.com/1741-7015/10/13
Page 6 of 12
of patients with GA have evidence of cerebellar atrophy
on magnetic resonance imaging. Even in those patients
without cerebellar atrophy, a proton magnetic resonance
spectroscopy of the cerebellum is abnormal.
The response to treatment with a GFD depends on
the duration of the ataxia prior to the diagnosis of GS.
Loss of Purkinje cells in the cerebellum, the end result
of prolonged gluten exposure in patients with GA, is
irreversible and prompt treatment is more likely to
result in improvement or stabilization of the ataxia.
The diagnosis of GA is not as straightforward as that
of CD. Anti-tTG2 IgA antibodies are only present in up
to 38% of patients, but often at lower titers than those
seen in patients with CD. However, unlike CD, IgG
class antibodies to tTG2 are more frequent than IgA.
Antibodies against tTG2 and tTG6 combined can be
found in 85% of patients with ataxia who are positive
for AGA antibodies [41]. It is unclear at present whether
combined detection of anti-tTG2 and anti-tTG6 IgA
and IgG without the use of AGA identifies all patients
with gluten ataxia.
The current recommendation is that patients present-
ing with progressive cerebellar ataxia should be screened
for GS using AGA IgG and IgA, anti-tTG2 antibodies
and, if available, IgG and IgA anti-tTG6 antibodies.
Patients with positive anti-tTG2 antibodies should
undergo a duodenal biopsy. However, irrespective of the
presence of an enteropathy, patients positive for any of
these antibodies with no alternative cause for their
ataxia should be offered a strict GFD with regular fol-
low-up to ensure that the antibodies are eliminated,
which usually takes six to twelve months. Stabilization
or even improvement of the ataxia after one year would
be a strong indicator that the patient suffers from GA.
Immune-mediated form (onset: hours to days after gluten
exposure)
Gluten sensitivity
The recent rise of the gluten-free market in the USA
(Figure 3), partially sustained by individuals who claim a
medical necessity to undertake a GFD, raises questions
about possible gluten reactions alternative to CD and
WA. It is now becoming clear that, besides CD and
WA, there are cases of gluten reactions in which neither
allergic nor autoimmune mechanisms can be identified.
These are generally defined as non-celiac GS or more
simply, GS. Some individuals who experience distress
when eating gluten-containing products and show
improvement when following a GFD may have GS
instead of CD. GS is a condition distinct from CD and
is not accompanied by the concurrence of anti-tTG
autoantibodies or other autoimmune comorbidities [44].
The small intestine of GS patients is usually normal
[44]. However, the two conditions cannot be
distinguished clinically, since the symptoms experienced
by GS patients are often seen in CD. We propose as a
definition of GS those cases of gluten reaction in which
both allergic and autoimmune mechanisms have been
ruled out (diagnosis by exclusion criteria). More specifi-
cally, these are cases with negative immuno-allergy tests
to wheat or negative CD serology (anti-EMA and/or
anti-tTG); where IgA deficiency has been ruled out;
with normal duodenal histopathology; with the possible
presence of biomarkers of native gluten immune-reac-
tion (AGA+); with clinical symptoms that can overlap
with CD or WA symptoms; and patients who show a
resolution of symptoms when started on a GFD, imple-
mented in a blinded fashion to avoid a possible placebo
effect of the dietary intervention.
The symptoms in GS may resemble those associated
with CD but with a prevalence of extraintestinal symp-
toms, such as behavioral changes, bone or joint pain,
muscle cramps, leg numbness, weight loss and chronic
fatigue. Between 2004 and 2010, 5,896 patients were
seen at the Center for Celiac Research, University of
Maryland. The criteria for GS were fulfilled by 347
(1:17; 6%) of the patients seen. Their symptoms included
abdominal pain (68%); eczema and/or rash (40%); head-
ache (35%); ‘foggy mind’ (34%); fatigue (33%); diarrhea
(33%); depression (22%); anemia (20%); numbness in the
legs, arms or fingers 20%; and joint pain (11%).
While the class II MHC haplotype HLA-DQ2 and
HLA-DQ8 are present in almost all CD patients, these
Figure 3 Trend of three different diets (low carbohydrate diet,
fat-free diet, and gluten-free diet), in the USA during the
period 2004 to 2011. For the American general population,
adopting a gluten-free diet is becoming an increasingly popular
option. The market for gluten-free food and beverage products
grew at a compound annual growth rate of 28% from 2004 to
2011, eclipsing the low carbohydrate diet and the fat-free diet in
2008, to finish with almost $1.6 billion in retail sales in 2010. By
2012 the market is expected to reach about $2.6 billion in sales. The
fact that approximately three million Americans suffer from celiac
disease and only a fraction of these patients have been diagnosed
implies that patients suffering other forms of proven gluten
reaction, including gluten sensitivity and wheat allergy, contribute
to this market growth. The rest of the market is filled either by
people who undertake the diet as occasional consumers (no
medical necessity) or by individuals affected by maladies that have
been claimed to be affected by gluten exposure, including autism
spectrum disorder, attention deficit hyperactivity disorder, multiple
sclerosis and irritable bowel syndrome, but for which there is no
evidence of the effectiveness of the diet.
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genes are present in only about 50% of patients with GS,
a percentage still higher compared to the general popu-
lation [45,46]. Similarly, an association of HLA-DQ2
with GS in diarrhea-predominant irritable bowel syn-
drome (IBS) has been reported [47]. Therefore the
involvement of an MHC-dependent, adaptive immune
response in GS is currently unclear and requires further
research. During the last decade, several studies have
identified signs and symptoms associated with non-
celiac GS, particularly concerning neuropsychiatric dis-
orders. Patients with schizophrenia have higher than
expected titers of AGA, which are related to CD and
GS, whereas the implementation of a GFD seems to
improve the behavior of a subset of children with autism
spectrum disorders (ASD) [48,49]. However, currently
there are no laboratory biomarkers specific for GS.
Usually the diagnosis is based on exclusion criteria; an
elimination diet of gluten-containing foods followed by
an open challenge is most often used to evaluate
whether health improves with the elimination or reduc-
tion of gluten from the patient’s diet.
Pathogenesis Under physiological conditions, the first
contact between food antigens and the local immune
system in the gut occurs through the interaction of anti-
gen-presenting cells, specifically dendritic cells that
sense luminal contents and promote tolerance toward
luminal food antigens, thus maintaining a disease-free
state [50-57]. The maintenance of tolerance requires
high differentiation and maturation of both epithelial
and immune cell compartments, and even a minimal
perturbation of this delicate balance may result in
pathological conditions. Unfortunately, evidence-based
information in this area is limited, but it is well accepted
that undigested or partly digested gliadin can affect a
wide range of human cell functions. Early introduction
of gliadin-containing cereals was recently reported to
increase the risk of islet cell autoimmunity in humans
[58]. Findings from studies using non-obese diabetic
mice and BioBreeding diabetic-prone (BBDP) rats have
implicated wheat gliadin as a dietary diabetogenic factor.
In BBDP rats, gliadin exposure is accompanied by zonu-
lin-dependent increased intestinal permeability, presum-
ably allowing food antigens to come in contact with the
underlying lamina propria [59]. Zonulin is an important
protein released by the small intestinal mucosa after sev-
eral stimuli (for example, dietary antigens, including glu-
ten (see Figure 2) or bacteria) and is involved in the
modulation of paracellular intestinal permeability. A
normal intestinal epithelium is impermeable to macro-
molecules, while CD is characterized by enhanced
intestinal permeability and an altered junctional struc-
ture between epithelial cells, leading to compromised
barrier function. Tight junctions (tj) and multiple pro-
teins that make up the tj strands (for example, occludin,
the claudin family, zonula occludens-1 protein (ZO-1))
have a critical role in the development of intestinal
immunological responsiveness. When the integrity of
the intestinal tj is compromised, an immune response to
environmental antigens that cross-react with host anti-
gens may develop, thereby triggering the onset of CD
[60,61]. Conversely, in a study conducted by Sapone et
al., GS subjects showed a normal intestinal permeability
and claudin-1 and ZO-1 expression compared to celiac
patients, and a significantly higher expression of clau-
din-4. In the same GS patients, the up-regulation of
claudin-4 was associated with an increased expression of
toll-like receptor-2 and a significant reduction of T-reg-
ulatory cell marker FoxP3 relative to controls and CD
patients. Additionally, an increase in IELs of the classes
a and b, but no increase in adaptive immunity-related
gut mucosal gene expression, including interleukin (IL)-
6, IL-21 and interferon -g, was detected in GS [62].
These changes in GS could suggest an important role of
the innate immune system without any involvement of
the adaptive immune response [62]. In vitro studies sug-
gest that wheat amylase-trypsin inhibitors (ATIs) could
play a major role as triggers of the innate immune
response in GS. Wheat ATIs are a family of five or
more homologous small proteins highly resistant to
intestinal proteolysis. They are known to be the major
allergen responsible for baker’s asthma. Preliminary evi-
dence suggests that the addition of 1 μg/mL to 20 μg/
mL of ATIs to monocyte-derived dendritic cells stimu-
lates the release of IL-8 in a dose-dependent manner
(Detlef Schuppan, unpublished data). Recently, to test
the hypothesis that gluten can cause gastrointestinal
symptoms in patients without CD, a double-blind, ran-
domized, placebo-controlled re-challenge trial was
undertaken in patients with IBS fulfilling the Rome cri-
teria III, who had CD excluded by best practice methods
and who reported a symptom response to a GFD [63].
Patients were randomized according to a computer-gen-
erated list of random numbers held by an independent
observer to either the gluten or the placebo treatment
group. Over the entire study period, the severity scores
of pain, satisfaction with stool consistency and tiredness
were significantly higher for those consuming the gluten
diet compared to the placebo group, while no evidence
for intestinal inflammation or damage or for latent CD
was found to offer an explanation for symptom dete-
rioration caused by gluten. Therefore, this study further
supports the notion that non-celiac GS is part of the
spectrum of gluten-related disorders and confirmed
similar findings reported more than 30 years ago [64].
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Algorithm to differentiate the different forms of gluten-
related disorders
Based on a combination of clinical, biological, genetic
and histological data, it is possible to differentiate the
three conditions (WA, CD and GS), following the algo-
rithm shown in Figure 4. In most cases, information
coming from clinical presentation will be sufficient to
distinguish between WA and the remaining two forms
of gluten-related disorders (CD and GS). Determination
of specific biomarkers for WA and CD is the proper
first step in the diagnostic process including gluten chal-
lenge (WA) or intestinal biopsy (CD). If these forms
have been excluded and other possible causes of the
symptoms experienced by patients have been ruled out,
then GS should be considered. A double-placebo gluten
challenge will be the final step to either confirm or rule
out GS.
Treatment with the GFD
In general, treatment of gluten-related disorders is based
on excluding gluten-containing cereals from the diet.
Wheat, barley and rye proteins are completely excluded
in a GFD. A wide range of attractive and palatable glu-
ten-free wheat substitutes that guarantee the absence of
gluten are specifically manufactured for patients with
CD and other gluten-related disorders. These products
are labeled by an internationally recognized mark, the
crossed ear of wheat. Patients with CD not only need to
be treated for life, but also require a very accurate treat-
ment, as gluten traces may still be able to induce
damage to their small intestinal mucosa. On the other
hand, the natural history of other gluten-related disor-
ders, particularly GS, is still unclear. Further studies are
urgently required to clarify whether the spectrum of
toxic cereals, the gluten threshold and the disease dura-
tion are the same in gluten allergy and/or sensitivity as
in CD.
Through the years, a GFD has been experimentally
applied to schizophrenia, multiple sclerosis, ASD and
dementia, to name only a few instances. The evidence
that the diet is effective in any of these areas is still con-
troversial, as a placebo effect of the dietary treatment is
often difficult to eliminate. ‘Allergy’ is currently all the
HistoryandPhysicalExamͲ InitialEvaluation–
ConsiderDifferentialDiagnosis
WheatAllergy(WA) CeliacDisease(CD)GlutenSensitivity(GS)
• Specificskinpricktests
• WheatspecificserumIgE
• Glutenchallenge
Tests+
Challenge+
YES
NO
WAdiagnosisconfirmed
tTG and/or
dAGA+
YES
NOWAruledout
• tTG IgA+/Ͳ EMA+totalIgA
• Deamidated AGAIgA
• AGA
EGDwith
biopsies
Suspected
GS
Biopsy
positive
Gluten
challenge+
YES
GSdiagnosis
confirmed
NO
GSruledout
Considerother
diagnoses
YES
NOPotentialCD
CDdiagnosis
confirmed
Figure 4 Proposed algorithm for the differential diagnosis of gluten-related disorders, including celiac disease, gluten sensitivity and
wheat allergy.
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rage, and it is well possible that many individuals are on
a GFD for no sound medical reasons. In these cases, the
diagnostic algorithm described in this paper will help to
select patients who really need treatment with a GFD.
Conclusions
It is now becoming apparent that reactions to gluten are
not limited to CD, rather we now appreciate the exis-
tence of a spectrum of gluten-related disorders. The
high frequency and wide range of adverse reactions to
gluten raise the question as to why this dietary protein
is toxic for so many individuals in the world. One possi-
ble explanation is that the selection of wheat varieties
with higher gluten content has been a continuous pro-
cess during the last 10,000 years, with changes dictated
more by technological rather than nutritional reasons.
Wheat varieties grown for thousands of years and
mostly used for human nutrition up to the Middle Ages,
such as Triticum monococcum and T. dicoccum, contain
less quantities of the highly toxic 33-mer gluten peptide
[65]. Apparently the human organism is still largely vul-
nerable to the toxic effects of this protein complex, par-
ticularly due to a lack of adequate adaptation of the
gastrointestinal and immunological responses.
Additionally, gluten is one of the most abundant and
diffusely spread dietary components for most popula-
tions, particularly those of European origin. In Europe,
the mean consumption of gluten is 10 g to 20 g per day,
with segments of the general population consuming as
much as 50 g of daily gluten or more [66,67] All indivi-
duals, even those with a low degree of risk, are therefore
susceptible to some form of gluten reaction during their
life span. Therefore, it is not surprising that during the
past 50 years we have witnessed an ‘epidemic’ of CD
[68,69] and the surging of new gluten-related disorders,
including the most recently described GS [44,62]. This
review provides some rationale to explain these epide-
miological phenomena and expands our current knowl-
edge to gain more insights into gluten-related disorders.
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